{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:52:25Z","timestamp":1792378345915,"version":"4.4.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.drudis.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T14:00:40Z","timestamp":1499176840000},"page":"1707-1718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":231,"title":["Mouse models of nonalcoholic steatohepatitis in preclinical drug development"],"prefix":"10.1016","volume":"22","author":[{"given":"Henrik H.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne S.","family":"Veidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer T.","family":"Rigbolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vrang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keld","family":"Fosgerau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2017.06.007_bib0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/liv.13299","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.drudis.2017.06.007_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.13301","article-title":"Pathology of non-alcoholic fatty liver disease","volume":"37","author":"Bedossa","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.drudis.2017.06.007_bib0025","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","article-title":"Liver transplantation for nonalcoholic steatohepatitis","volume":"256","author":"Agopian","year":"2012","journal-title":"Ann. Surg."},{"key":"10.1016\/j.drudis.2017.06.007_bib0040","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0045","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u2018hits\u2019?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0050","first-page":"9038","article-title":"Translational approaches: from fatty liver to non-alcoholic steatohepatitis","volume":"20","author":"Rosso","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0055","first-page":"221","article-title":"Molecular pathways in non-alcoholic fatty liver disease","volume":"7","author":"Berlanga","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0060","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3892\/ijmm.2015.2264","article-title":"Identification of novel targets for the diagnosis and treatment of liver fibrosis","volume":"36","author":"Fagone","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.drudis.2017.06.007_bib0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2016.05.051","article-title":"Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients","volume":"151","author":"Teufel","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0070","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0075","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s00535-013-0766-5","article-title":"Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease","volume":"48","author":"Tokushige","year":"2013","journal-title":"J. Gastroenterol."},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2017.06.007_bib0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12072-013-9468-6","article-title":"Immune and inflammatory pathways in NASH","volume":"7","author":"Ganz","year":"2013","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.drudis.2017.06.007_bib0085","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.3390\/ijms15058591","article-title":"Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation","volume":"15","author":"Peverill","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2017.06.007_bib0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0095","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/1389450116666150531153627","article-title":"IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression","volume":"16","author":"Giles","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.drudis.2017.06.007_bib0100","doi-asserted-by":"crossref","first-page":"G270","DOI":"10.1152\/ajpgi.00304.2014","article-title":"Hepatic TLR4 signaling in obese NAFLD","volume":"309","author":"Sharifnia","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.24341","article-title":"Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells","volume":"54","author":"Csak","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.drudis.2015.10.015","article-title":"Emerging therapeutic targets for the treatment of hepatic fibrosis","volume":"21","author":"Fagone","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2017.06.007_bib0120","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrd.2015.3","article-title":"Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies","volume":"15","author":"Musso","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2017.06.007_bib0130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cgh.2014.08.039","article-title":"Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis","volume":"13","author":"Patel","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0135","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0140","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0145","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1053\/j.gastro.2016.03.008","article-title":"Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease","volume":"150","author":"Bedossa","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0150","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0155","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0160","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0165","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0170","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X. nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2017.06.007_bib0175","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0180","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2017.06.007_bib0185","doi-asserted-by":"crossref","first-page":"e115922","DOI":"10.1371\/journal.pone.0115922","article-title":"Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology","volume":"9","author":"Liang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.06.007_bib0190","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.12335","article-title":"Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype","volume":"34","author":"Farrell","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.drudis.2017.06.007_bib0195","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1440-1746.2007.05150.x","article-title":"Interstrain differences in susceptibility to non-alcoholic steatohepatitis","volume":"23","author":"Yamazaki","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0200","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejphar.2008.01.045","article-title":"Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice","volume":"584","author":"Zheng","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/9185987","article-title":"A combination of leucine, metformin, and sildenafil treats nonalcoholic fatty liver disease and steatohepatitis in mice","volume":"2016","author":"Bruckbauer","year":"2016","journal-title":"Int. J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/574832","article-title":"Nonalcoholic steatohepatitis: a search for factual animal models","volume":"2015","author":"Sanches","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.drudis.2017.06.007_bib0215","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","article-title":"Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice","volume":"302","author":"Trevaskis","year":"2012","journal-title":"AJP Gastrointest. Liver Physiol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0220","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2017.06.007_bib0225","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.28962","article-title":"A novel glucagon-like peptide 1\/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice","volume":"65","author":"Valdecantos","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0230","doi-asserted-by":"crossref","first-page":"G987","DOI":"10.1152\/ajpgi.90272.2008","article-title":"Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent","volume":"295","author":"Tetri","year":"2008","journal-title":"AJP Gastrointest. Liver Physiol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0235","doi-asserted-by":"crossref","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","article-title":"Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment","volume":"305","author":"Clapper","year":"2013","journal-title":"AJP Gastrointest. Liver Physiol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0240","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","article-title":"Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy","volume":"8","author":"Kristiansen","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0245","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jnutbio.2014.11.002","article-title":"Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis","volume":"26","author":"Mells","year":"2015","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.drudis.2017.06.007_bib0250","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer","volume":"65","author":"Asgharpour","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0255","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/oby.21701","article-title":"Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice","volume":"25","author":"Haczeyni","year":"2017","journal-title":"Obesity"},{"key":"10.1016\/j.drudis.2017.06.007_bib0260","first-page":"S16","article-title":"YH25724, a novel long-acting GLP-1\/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models","volume":"66","author":"Kim","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0265","series-title":"The 2nd NASH Summit","article-title":"Comparative metabolic and hepatic effects of liraglutide, elafibranor and obeticholic acid in diet-induced and genetically obese mouse models of biopsy-confirmed NASH","author":"Feigh","year":"2017"},{"key":"10.1016\/j.drudis.2017.06.007_bib0270","doi-asserted-by":"crossref","first-page":"18528","DOI":"10.1074\/jbc.M109.099333","article-title":"Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial s-adenosyl-l-methionine and GSH","volume":"285","author":"Caballero","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2017.06.007_bib0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.metabol.2016.12.013","article-title":"Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice","volume":"69","author":"Honda","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.drudis.2017.06.007_bib0280","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0285","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2004.06.030","article-title":"Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet","volume":"41","author":"Koppe","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0290","doi-asserted-by":"crossref","first-page":"e0164191","DOI":"10.1371\/journal.pone.0164191","article-title":"Evaluation of methionine content in a high-fat and choline-deficient diet on body weight gain and the development of non-alcoholic steatohepatitis in mice","volume":"11","author":"Chiba","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.06.007_bib0295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-4939-6786-5_19","article-title":"Optimized mouse models for liver fibrosis","volume":"1559","author":"Kim","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0300","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1383-5742(02)00044-3","article-title":"Genotoxicity of streptozotocin","volume":"512","author":"Bolz\u00e1n","year":"2002","journal-title":"Mutat. Res."},{"key":"10.1016\/j.drudis.2017.06.007_bib0305","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"Fujii","year":"2013","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0310","doi-asserted-by":"crossref","first-page":"12466","DOI":"10.1038\/srep12466","article-title":"Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis","volume":"5","author":"Saito","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2017.06.007_bib0315","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fendo.2016.00145","article-title":"How useful are monogenic rodent models for the study of human non-alcoholic fatty liver disease?","volume":"7","author":"Mann","year":"2016","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0320","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0168-8278(02)00102-2","article-title":"Leptin is essential for the hepatic fibrogenic response to chronic liver injury","volume":"37","author":"Leclercq","year":"2002","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0325","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","article-title":"The LXR inverse agonist SR. 9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis","volume":"4","author":"Griffett","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.drudis.2017.06.007_bib0330","doi-asserted-by":"crossref","first-page":"e0146337","DOI":"10.1371\/journal.pone.0146337","article-title":"The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.06.007_bib0335","series-title":"The FXR\/TGR5 dual agonist INT-767 reduces NAFLD activity score and fibrosis stage and improves plasma and hepatic lipid profiles in the GUBRA-AMLN mouse model of diet-induced and biopsy-confirmed nonalcoholic steatohepatitis","first-page":"144401","author":"Roth","year":"2016"},{"key":"10.1016\/j.drudis.2017.06.007_bib0340","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2613.2011.00793.x","article-title":"Pathology of the liver in obese and diabetic ob\/ob and db\/db mice fed a standard or high-calorie diet","volume":"92","author":"Trak-Smayra","year":"2011","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0345","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0350","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3748\/wjg.v22.i8.2512","article-title":"Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice","volume":"22","author":"Yamamoto","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0355","doi-asserted-by":"crossref","first-page":"e0124081","DOI":"10.1371\/journal.pone.0124081","article-title":"Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL\/KsJ-+Leprdb\/+Leprdb mice","volume":"10","author":"Ohno","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.06.007_bib0360","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1210\/me.2005-0494","article-title":"Fat Aussie\u2014a new Alstr\u00f6m Syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis","volume":"20","author":"Arsov","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0365","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jhep.2013.02.024","article-title":"Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome","volume":"59","author":"Van Rooyen","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0370","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/ijo.2011.55","article-title":"Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice","volume":"35","author":"Bell-Anderson","year":"2011","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.drudis.2017.06.007_bib0375","first-page":"269","article-title":"The FLS mouse: a new inbred strain with spontaneous fatty liver","volume":"49","author":"Soga","year":"1999","journal-title":"Lab. Anim. Sci."},{"key":"10.1016\/j.drudis.2017.06.007_bib0380","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1872-034X.2012.01101.x","article-title":"Fatty liver Shionogi- ob\/ob mouse: a new candidate for a non-alcoholic steatohepatitis model","volume":"43","author":"Sugihara","year":"2013","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drudis.2017.06.007_bib0385","doi-asserted-by":"crossref","first-page":"12931","DOI":"10.1038\/srep12931","article-title":"Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis","volume":"5","author":"Schierwagen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2017.06.007_bib0390","doi-asserted-by":"crossref","first-page":"e30668","DOI":"10.1371\/journal.pone.0030668","article-title":"LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease","volume":"7","author":"Bieghs","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.06.007_bib0395","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1111\/bph.13315","article-title":"Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes","volume":"172","author":"Liang","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0400","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0405","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/JOE-15-0469","article-title":"The role of bile acids in metabolic regulation","volume":"228","author":"V\u00edtek","year":"2016","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0410","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.4254\/wjh.v7.i28.2811","article-title":"Bile acid receptors and nonalcoholic fatty liver disease","volume":"7","author":"Yuan","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0415","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.drudis.2017.06.007_bib0420","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.gastro.2009.09.015","article-title":"Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition","volume":"138","author":"Kluwe","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0425","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s10753-017-0528-2","article-title":"A20 attenuates liver fibrosis in NAFLD and inhibits inflammation responses","volume":"40","author":"Wang","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.drudis.2017.06.007_bib0430","doi-asserted-by":"crossref","first-page":"53","DOI":"10.14218\/JCTH.2014.00035","article-title":"Animal models for fibrotic liver diseases: what we have, what we need, and what is under development","volume":"3","author":"Delire","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0435","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29246","article-title":"Acetyl-CoA carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study","author":"Stiede","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0440","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/dmrr.2713","article-title":"Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies","volume":"32","author":"Tang","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.drudis.2017.06.007_bib0445","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2017.06.007_bib0450","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1053\/j.gastro.2016.08.027","article-title":"In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores","volume":"151","author":"Schwimmer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0455","first-page":"1119A","article-title":"GS-4997, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH): A randomized, Phase 2 trial","volume":"64","author":"Loomba","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0460","doi-asserted-by":"crossref","first-page":"e0175717","DOI":"10.1371\/journal.pone.0175717","article-title":"A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis","volume":"12","author":"McPherson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.06.007_bib0465","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.24558","article-title":"Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial","volume":"54","author":"Torres","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0470","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2213-8587(13)70170-0","article-title":"Inhibition of 11\u03b2-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Stefan","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0475","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/MEG.0000000000000068","article-title":"Pentoxifylline for the treatment of nonalcoholic fatty liver disease","volume":"26","author":"Zeng","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0480","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/S0168-8278(15)30191-4","article-title":"A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases","volume":"62","author":"Shiffman","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0485","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.24747","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis","volume":"55","author":"Ratziu","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0490","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.12887","article-title":"Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis","author":"Nakade","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drudis.2017.06.007_bib0495","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.drudis.2017.06.007_bib0500","first-page":"1118","article-title":"Cenicriviroc versus placebo for the treatment of nonalcoholic steatohepatitis with liver fibrosis: results from the Year 1 primary analysis of the Phase 2b CENTAUR study","volume":"64","author":"Sanyal","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0505","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs: placebo for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0510","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2017.06.007_bib0515","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0520","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0525","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/apt.13981","article-title":"Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease","volume":"45","author":"Kim","year":"2017","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2017.06.007_bib0530","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.cgh.2014.01.040","article-title":"Lack of efficacy of an inhibitor of PDE4 in Phase 1 and 2 trials of patients with nonalcoholic steatohepatitis","volume":"12","author":"Ratziu","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0535","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4254\/wjh.v5.i9.470","article-title":"Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease","volume":"5","author":"Kostapanos","year":"2013","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0540","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0545","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40261-016-0383-1","volume":"36","author":"Ohki","year":"2016","journal-title":"Drug Investig."},{"key":"10.1016\/j.drudis.2017.06.007_bib0550","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0555","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/labinvest.2016.61","article-title":"C\/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis","volume":"96","author":"Rahman","year":"2016","journal-title":"Lab. Invest."},{"key":"10.1016\/j.drudis.2017.06.007_bib0560","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejphar.2017.02.043","article-title":"APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL\/6 mice","volume":"801","author":"Bahirat","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0565","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARa agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0570","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1073\/pnas.1525093113","article-title":"Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease","volume":"113","author":"Liu","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drudis.2017.06.007_bib0575","doi-asserted-by":"crossref","first-page":"e92273","DOI":"10.1371\/journal.pone.0092273","article-title":"Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation In vitro by inhibition of FGF, VEGF and PDGF signaling","volume":"9","author":"Nakamura","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.06.007_bib0580","doi-asserted-by":"crossref","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the Dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.06.007_bib0585","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00795-013-0053-9","article-title":"Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis","volume":"47","author":"Klein","year":"2014","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0590","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejphar.2015.12.043","article-title":"Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model","volume":"772","author":"Orime","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0595","first-page":"4750","article-title":"An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function","volume":"8","author":"Lee","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.drudis.2017.06.007_bib0600","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am. J. Physiol. \u2212 Gastrointest. Liver Physiol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0605","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23941","article-title":"Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice","volume":"52","author":"Gupte","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2017.06.007_bib0610","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/hepr.12092","article-title":"Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse","volume":"44","author":"Wang","year":"2014","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drudis.2017.06.007_bib0615","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1478-3231.2006.01265.x","article-title":"Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver","volume":"26","author":"Harano","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.drudis.2017.06.007_bib0620","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.3892\/mmr.2015.4329","article-title":"Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob\/ob male mice","volume":"12","author":"Onoyama","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.drudis.2017.06.007_bib0625","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/hepr.12186","article-title":"Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob\/ob male mice","volume":"44","author":"Kishina","year":"2014","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drudis.2017.06.007_bib0630","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4254\/wjh.v8.i22.933","article-title":"Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model","volume":"8","author":"Okamoto","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0635","first-page":"107","article-title":"Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob\/ob male mice","volume":"30","author":"Koda","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.drudis.2017.06.007_bib0640","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2017.06.007_bib0645","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2016.11.006","article-title":"Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation","volume":"314","author":"Zhang","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644617300272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644617300272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:31:26Z","timestamp":1761222686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644617300272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":129,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1359644617300272"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2017.06.007","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mouse models of nonalcoholic steatohepatitis in preclinical drug development","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}